{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-26-000045","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2026-08-06T20:32:07+00:00","discovered_at":"2026-08-06T20:33:04.409038+00:00","generated_at":"2026-08-06T20:33:17.793293+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Amphastar Q2 2026 revenue up 5.4% YoY to $183.9M; adjusted EPS $0.91","bullets":["Net revenues of $183.9M for Q2 2026, up from $174.4M in Q2 2025.","GAAP net income $30.3M ($0.67 diluted EPS) vs $31.0M ($0.64) year ago.","Adjusted non-GAAP net income $40.8M ($0.91 diluted EPS) vs $40.9M ($0.85).","CEO cites revenue growth, gross margin expansion, new product launches, and pipeline progress.","Six-month 2026 GAAP net income $36.8M ($0.81) vs $56.3M ($1.15) in prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-26-000045","json":"https://secwatch.observer/filing/0001297184-26-000045.json","markdown":"https://secwatch.observer/filing/0001297184-26-000045.md","text":"https://secwatch.observer/filing/0001297184-26-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/0001297184-26-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/amph-20260806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:33:17.793293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}